Protein Summary
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFR2. Dihydrofolate reductase converts dihydrofolate into tetrahydrofolate, a methyl group shuttle required for the de novo synthesis of purines, thymidylic acid, and certain amino acids. While the functional dihydrofolate reductase gene has been mapped to chromosome 5, multiple intronless processed pseudogenes or dihydrofolate reductase-like genes have been identified on separate chromosomes. Dihydrofolate reductase deficiency has been linked to megaloblastic anemia. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2014]
- ENST00000439211
- ENSP00000396308
- ENSG00000228716
- ENST00000504396
- ENSP00000421334
- ENST00000505337
- ENSP00000426474
- DYR
- DHFRP1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
transcription factor perturbation | 0.98 | ||
disease | 0.95 | ||
drug | 0.94 | ||
histone modification site profile | 0.93 | ||
kinase perturbation | 0.81 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1653.98 (req: < 5)
Gene RIFs: 105 (req: <= 3)
Antibodies: 277 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 1653.98 (req: >= 5)
Gene RIFs: 105 (req: > 3)
Antibodies: 277 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 23
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 633
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 7